Three Aurora-kinase inhibitors have recently been described — ZM447439, Hesperadin and VX-680. All three induce similar phenotypes in cell-based assays and, interestingly, ...

Aurora Kinase inhibitors The dawn of a new approach to cancer. Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of ...

Aurora kinase inhibitors suppress this adaptive survival program, increasing the magnitude and duration of EGFR inhibitor response in pre-clinical models. Treatment induced activation of AURKA was ...

The aurora kinase inhibitor MK-0457 (VX-680) and the p38 MAP kinase inhibitor BIRB-796 were also reported to be effective against T315I.

VITRAC Therapeutics, LLC (VITRAC) presented a poster on the Phase 1a/1b clinical trial of aurora kinase A (AURKA) inhibitor, VIC-1911, as monotherapy ...

December 12, 2006 (Orlando) — A new aurora kinase inhibitor is the first to show clinical activity in a population of treatment-resistant leukemia patients with a poor prognosis. The new Merck ...

In vivo tests show how using an investigational drug to block Aurora kinase A improves effectiveness of an approved breast cancer drug and renders different breast ...

In preclinical models, combining an investigational Aurora Kinase A (AURKA) inhibitor with a KRAS inhibitor or a WEE1 inhibitor showed efficacy against lung cancer cells with intrinsic or acquired ...

Aurora kinases, a group of serine/threonine protein family, comprise Aurora A, B and C members and are involved in the regulation of cell division and mitosis. Aurora A overexpression correlates with ...

A new chemotherapy drug (alisertib or MLN8237) being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who ...